US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ATS Corp.

32.42

+0.40001.25%

Volume:75.54K

Turnover:2.43M

Market Cap:3.17B

PE:-160.69

High:32.42

Open:31.68

Low:31.57

Close:32.02

Loading ...

Overview Company News Filings

ATS's $135M Settlement Better Than Nothing -- Market Talk

ATS Corporation Settles with EV Customer and Reports Preliminary Q4 2025 Results

You can now buy NVIDIA on Kraken! What are the differences compared to trading stocks on a traditional brokerage?

Vicore Pharma Unveils Promising IPF Treatment Data at ATS Conference

Australis Oil & Gas Reports Successful AGM Resolutions

Australis Oil & Gas Focuses on Strategic Asset Management Amid Market Challenges

PureTech Health presents deupirfenidone data at ATS conference

Achieve Life Sciences to present new data at 2025 ATS International Conference

Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake

Zymeworks presents new ZW1528 data at ATS conference

aTyr Pharma presents three posters on efzofitimod at ATS 2025 Conference

Press Release: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Press Release: Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

New Era for Real-World Assets: What 2025 Means for Tokenization Projects

TD Securities Sticks to Their Buy Rating for ATS Corporation (ATS)

Press Release: aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

OTC Markets Group Welcomes Steel Partners Holdings L.P. to OTCQX

Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases

PureTech Health to Present Promising IPF Trial Results at ATS Conference

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ATS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATS\",,,,,undefined,":{"symbol":"ATS","market":"US","secType":"STK","nameCN":"ATS Corp.","latestPrice":32.42,"timestamp":1751477184438,"preClose":32.02,"halted":0,"volume":75536,"delay":0,"floatShares":81275035,"shares":97634402,"eps":-0.20176,"marketStatus":"Trading","change":0.4,"latestTime":"07-02 13:27:45 EDT","open":31.68,"high":32.42,"low":31.565,"amount":2430898.79664,"amplitude":0.026702,"askPrice":32.5,"askSize":200,"bidPrice":32.4,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-0.20176,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1751486400000},"marketStatusCode":2,"adr":0,"listingDate":1684987200000,"exchange":"NYSE","adjPreClose":32.02,"postHourTrading":{"tag":"盘后","latestPrice":32.02,"preClose":32.02,"latestTime":"16:46 EDT","volume":37822,"amount":1211060.44,"timestamp":1751402761239},"volumeRatio":1.667544,"impliedVol":0.2433,"impliedVolPercentile":0.108},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATS\",,,,,undefined,":{"symbol":"ATS","floatShares":81275035,"roa":"0.94%","roe":"-1.65%","lyrEps":-0.199176,"volumeRatio":1.667544,"shares":97634402,"dividePrice":0,"high":32.42,"amplitude":0.026702,"preClose":32.02,"low":31.565,"week52Low":20.9,"pbRate":"2.52","psRate":"1.70","week52High":34.32,"institutionHeld":0,"latestPrice":32.42,"committee":-0.818182,"eps":-0.20176,"divideRate":0,"volume":75536,"delay":0,"ttmEps":-0.20176,"open":31.68,"prevYearClose":30.48,"prevWeekClose":31.7,"prevMonthClose":31.88,"prevQuarterClose":31.88,"fiveDayClose":31.09,"twentyDayClose":29.74,"sixtyDayClose":23.5},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538105535","title":"ATS's $135M Settlement Better Than Nothing -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2538105535","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538105535?lang=en_us&edition=fundamental","pubTime":"2025-05-26 20:03","pubTimestamp":1748260980,"startTime":"0","endTime":"0","summary":"1203 GMT - ATS managed to get some money from a settlement with a large EV customer, but only about half what it was due. ATS will receive about $145.8 million from the customer, which represents only about 57% of the $340 million balance despite services rendered, TD Cowen analyst Cherilyn Radbourne notes. However, Radbourne says that despite this, there are positives, including a substantial cash inflow at a time when the EV sector faces tariff and macroeconomic uncertainty. \"It's disappointing to see ATS receive less than full payment despite satisfying the contracts, however we see this as a positive outcome,\" she says. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATS","BK4161"],"gpt_icon":0},{"id":"2537375164","title":"ATS Corporation Settles with EV Customer and Reports Preliminary Q4 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2537375164","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537375164?lang=en_us&edition=fundamental","pubTime":"2025-05-24 12:02","pubTimestamp":1748059340,"startTime":"0","endTime":"0","summary":"ATS Corporation ( ($TSE:ATS) ) has issued an announcement. ATS Corporation has reached a settlement agreement with an electric vehicle customer, re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ats-corporation-settles-with-ev-customer-and-reports-preliminary-q4-2025-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ats-corporation-settles-with-ev-customer-and-reports-preliminary-q4-2025-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATS","BK4161"],"gpt_icon":0},{"id":"2537186513","title":"You can now buy NVIDIA on Kraken! What are the differences compared to trading stocks on a traditional brokerage?","url":"https://stock-news.laohu8.com/highlight/detail?id=2537186513","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537186513?lang=en_us&edition=fundamental","pubTime":"2025-05-23 16:45","pubTimestamp":1747989900,"startTime":"0","endTime":"0","summary":"In recent years, an increasing number of institutions and regulatory bodies in the traditional financial sector have begun to accept cryptocurrency, and more and more projects in the crypto space are intending to comply in exchange for greater exposure. The road to Build is long, but the explosion is instantaneous, with several trend indicators such as the inauguration of the Trump administration, a shift in the SEC's stance, the recent stablecoin legislation passage, and the inclusion of the cryptocurrency exchange Coinbase in the S&P 500 index.This has led many previously cautious crypto projects and brokerage firms to boldly engage in security tokenization business, and a proliferation of on-chain \"Nasdaqs\" has emerged.Where Else Can You Buy \"On-Chain Stocks\"?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info/en/news/58301","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_highlight","symbols":["SNVD.UK","IE00BFSS8Q28.SGD","LU0265550946.USD","IE00B1BXHZ80.USD","LU0348723411.USD","TSYW.SI","NVIW.SI","NVDS.UK","LU2458330169.SGD","NVD3.UK","NVDA","2NVD.UK","ETH.USD.HKCC","NVD2.UK","NVDY","LU1242518931.SGD","LU0203201768.USD","LU2133065610.SGD","NVD","TON.USD.CC","NVDX","LU2250418816.HKD","MACW.SI","LU2592432038.USD","IE00BKVL7J92.USD","MAS","LU2491050071.SGD","APT.USD.CC","USDT.USD.HKCC","SOL.USD.HKCC","NVDU","SG9999014559.SGD","APT.USD.HKCC","ATS","NVDS","LU0256863811.USD","LU0094547139.USD","TON.USD.HKCC","LU1923623000.USD","LU2092627202.USD","3NVD.UK","LU1244550494.USD","NVDD","ETH.USD.CC","USDT.USD.CC"],"gpt_icon":1},{"id":"2537991858","title":"Vicore Pharma Unveils Promising IPF Treatment Data at ATS Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2537991858","media":"TIPRANKS","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537991858?lang=en_us&edition=fundamental","pubTime":"2025-05-22 14:33","pubTimestamp":1747895606,"startTime":"0","endTime":"0","summary":"Vicore Pharma Holding AB ( ($SE:VICO) ) has provided an update. Vicore Pharma Holding AB presented new data at the 2025 American Thoracic Society I...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vicore-pharma-unveils-promising-ipf-treatment-data-at-ats-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vicore-pharma-unveils-promising-ipf-treatment-data-at-ats-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATS","BK4161"],"gpt_icon":0},{"id":"2537899183","title":"Australis Oil & Gas Reports Successful AGM Resolutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2537899183","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537899183?lang=en_us&edition=fundamental","pubTime":"2025-05-22 14:23","pubTimestamp":1747894989,"startTime":"0","endTime":"0","summary":"Australis Oil & Gas ( ($AU:ATS) ) just unveiled an announcement. Australis Oil & Gas Limited announced the successful passing of all six resolution...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/australis-oil-gas-reports-successful-agm-resolutions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/australis-oil-gas-reports-successful-agm-resolutions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4229","AGM","BK4195","ATS","BK4161"],"gpt_icon":0},{"id":"2537962921","title":"Australis Oil & Gas Focuses on Strategic Asset Management Amid Market Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2537962921","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537962921?lang=en_us&edition=fundamental","pubTime":"2025-05-22 10:57","pubTimestamp":1747882638,"startTime":"0","endTime":"0","summary":"Australis Oil & Gas ( ($AU:ATS) ) just unveiled an update. During the 2025 Annual General Meeting, Australis Oil & Gas Limited highlighted its effo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/australis-oil-gas-focuses-on-strategic-asset-management-amid-market-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/australis-oil-gas-focuses-on-strategic-asset-management-amid-market-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4161","ATS"],"gpt_icon":0},{"id":"2537626152","title":"PureTech Health presents deupirfenidone data at ATS conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2537626152","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537626152?lang=en_us&edition=fundamental","pubTime":"2025-05-21 05:25","pubTimestamp":1747776313,"startTime":"0","endTime":"0","summary":"PureTech Health (PRTC) delivered a late-breaking, oral presentation at the 2025 American Thoracic Society international conference in San Francisco...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/puretech-health-presents-deupirfenidone-data-at-ats-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/puretech-health-presents-deupirfenidone-data-at-ats-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRTC","BK4139","BK4161","ATS"],"gpt_icon":0},{"id":"2536617166","title":"Achieve Life Sciences to present new data at 2025 ATS International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2536617166","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536617166?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:35","pubTimestamp":1747744518,"startTime":"0","endTime":"0","summary":"Achieve Life Sciences (ACHV) announced that additional analyses from its Phase 3 ORCA-3 study will be presented during an oral presentation at the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/achieve-life-sciences-to-present-new-data-at-2025-ats-international-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/achieve-life-sciences-to-present-new-data-at-2025-ats-international-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4161","BK4139","ACHV","ATS"],"gpt_icon":0},{"id":"2536617928","title":"Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake","url":"https://stock-news.laohu8.com/highlight/detail?id=2536617928","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536617928?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:30","pubTimestamp":1747744200,"startTime":"0","endTime":"0","summary":"Oral Presentation to Highlight Key Benefits of Cytisinicline’s Dual Mechanism of Action to Pulmonary SpecialistsSEATTLE and VANCOUVER, British Columbia, May  20, 2025  (GLOBE NEWSWIRE) -- Achieve Life","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/05/20/3084886/0/en/Achieve-Life-Sciences-to-Present-New-Data-at-the-2025-ATS-International-Conference-Demonstrating-that-Cytisinicline-Reduced-Cravings-and-Nicotine-Intake.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATS"],"gpt_icon":0},{"id":"2536637734","title":"Zymeworks presents new ZW1528 data at ATS conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2536637734","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536637734?lang=en_us&edition=fundamental","pubTime":"2025-05-20 04:20","pubTimestamp":1747686014,"startTime":"0","endTime":"0","summary":"Zymeworks (ZYME) announced the presentation of new preclinical data for ZW1528, a novel IL-4Ra x IL-33 bispecific molecule designed to address resp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zymeworks-presents-new-zw1528-data-at-ats-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zymeworks-presents-new-zw1528-data-at-ats-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ATS","ZYME","BK4161"],"gpt_icon":0},{"id":"2536681657","title":"aTyr Pharma presents three posters on efzofitimod at ATS 2025 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2536681657","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536681657?lang=en_us&edition=fundamental","pubTime":"2025-05-19 20:20","pubTimestamp":1747657227,"startTime":"0","endTime":"0","summary":"aTyr Pharma (ATYR) announced three poster presentations for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society 2025 Inte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atyr-pharma-presents-three-posters-on-efzofitimod-at-ats-2025-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atyr-pharma-presents-three-posters-on-efzofitimod-at-ats-2025-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATS","ATYR","BK4161","BK4139"],"gpt_icon":0},{"id":"2535108870","title":"Press Release: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535108870","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535108870?lang=en_us&edition=fundamental","pubTime":"2025-05-16 04:09","pubTimestamp":1747339740,"startTime":"0","endTime":"0","summary":"RENEW Phase 2 trial evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis  initiated with topline interim data expected in the first half of 2026. Two abstracts accepted to the American Thoracic Society  2025 International Conference. Cash runway extended following previously announced warrant transactions and private placement. \"Rein has completed a multitude of key accomplishments since the beginning of the year, and we are particularly excited to have initiated the Phase 2 RENEW trial of LTI-03 in patients with IPF,\" said Brian Windsor, Ph.D., President and Chief Executive Officer of Rein Therapeutics. \"We have taken several strategic steps to prepare for this trial. Our LTI-03 program continues to evolve as we entered into a collaboration with Qureight to bring cutting-edge technology to our imaging and data analysis and obtained patents covering our novel formulation and administration methods. We are committed to continuing this momentum of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATS","BK4161","LENZ","BK4007","RNTX","BK4139","CSD","BK4539"],"gpt_icon":0},{"id":"2535828197","title":"Press Release: Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535828197","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535828197?lang=en_us&edition=fundamental","pubTime":"2025-05-15 21:00","pubTimestamp":1747314000,"startTime":"0","endTime":"0","summary":"Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in 1H 2026. Published positive data from its global Phase 2 study supporting potential of rademikibart as a novel biologic treatment for patients with asthma and Type 2 inflammation. Strong balance sheet with cash runway into 2027 through key clinical catalysts. SAN DIEGO, May 15, 2025  -- Connect Biopharma Holdings Limited  , a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease , today reported financial results for the three months ended March 31, 2025, and provided a business update.-- Executing on rapid clinical development program for rademikibart as an. -- Initiated Phase 2 Seabreeze STAT asthma study evaluating the. safety and efficacy of rademikibart for acute exacerbations in. adolescents and ad","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","ATS","BK4161","BK4139"],"gpt_icon":0},{"id":"2535551024","title":"New Era for Real-World Assets: What 2025 Means for Tokenization Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=2535551024","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535551024?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:49","pubTimestamp":1747226992,"startTime":"0","endTime":"0","summary":"For years, real-world assets  such as real estate, gold, and private equity were caught in outdated systems. They were difficult to trade, sluggish to process, and overburdened with paperwork. While the notion of placing these assets on the blockchain sounded terrific, the reality did not match the excitement.Most early RWA efforts were unable to overcome strict rules or establish sufficient confidence with huge organizations. Old restrictions enacted decades ago make it difficult to tokenize assets in a compliant manner. Many platforms made ambitious promises, but few really delivered anything beyond pilot projects or small-scale tests.That is finally changing. By 2025, RWA tokenization will be a reality rather than a hypothesis. Large institutions, government authorities, and blockchain platforms are starting to collaborate. Real-world assets are now being moved into the blockchain through regulated, high-value transactions across continents, from North America to the Middle East.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/68249173736240356fa56c01/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["MBG","ATS","BK4161"],"gpt_icon":0},{"id":"2535484687","title":"TD Securities Sticks to Their Buy Rating for ATS Corporation (ATS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535484687","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535484687?lang=en_us&edition=fundamental","pubTime":"2025-05-13 17:27","pubTimestamp":1747128428,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Cherilyn Radbourne from TD Securities maintained a Buy rating on ATS Corporation (ATS – Research Report), with a pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-securities-sticks-to-their-buy-rating-for-ats-corporation-ats-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-securities-sticks-to-their-buy-rating-for-ats-corporation-ats-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATS","TD"],"gpt_icon":0},{"id":"2533240965","title":"Press Release: aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2533240965","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533240965?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:01","pubTimestamp":1746648060,"startTime":"0","endTime":"0","summary":"Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025.Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be presented at ATS 2025.SAN DIEGO, May 07, 2025  -- aTyr Pharma, Inc.  , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced first quarter 2025 results and provided a corporate update.\"Throughout the first quarter of 2025 we have maintained strong and steady progress with our clinical program for efzofitimod in interstitial lung disease ,\" said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. \"The program's cornerstone is our Phase 3 EFZO-FIT study in pulmonary sarcoidosis, the most prevalent form of ILD for which no new treatments have been approved in mor","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","ATYR","BK4161","BK4139","TM","03160","BK4588","BK4604","BK4585","BK4555","ATS"],"gpt_icon":0},{"id":"2532817970","title":"OTC Markets Group Welcomes Steel Partners Holdings L.P. to OTCQX","url":"https://stock-news.laohu8.com/highlight/detail?id=2532817970","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532817970?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:00","pubTimestamp":1746183600,"startTime":"0","endTime":"0","summary":"NEW YORK, May 02, 2025  -- OTC Markets Group Inc. , operator of regulated markets for trading 12,000 U.S. and international securities, today announced Steel Partners Holdings L.P. , a diversified global holding company, has qualified to trade on the OTCQX Best Market. Steel Partners Holdings LP previously traded on the New York Stock Exchange.Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. Streamlined market requirements for OTCQX are designed to help companies lower the cost and complexity of being publicly traded, while providing transparent trading for their investors. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.OTC Markets Group Inc.  operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our three public markets: ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/otc-markets-group-welcomes-steel-110000181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4112","BK4161","SPLP","ATS","BK4206","OTCM"],"gpt_icon":0},{"id":"2532070899","title":"Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2532070899","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532070899?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:00","pubTimestamp":1746104400,"startTime":"0","endTime":"0","summary":"24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease  and asthma. COPD data from the landmark Phase 3 trials will highlight Dupixent impact on lung function and health-related quality of life across broad populations of patients with type 2 inflammation. Asthma abstracts include late-breaking data on mucus burden and the first presentation of efficacy results from a Phase 2 trial designed to study Dupixent in allergic bronchopulmonary aspergillosis  in patients with asthma. COPD data assess Dupixent impact on lung function and exacerbations in COPD, including patients with or without emphysema Notable abstracts in COPD will highlight new results from the pivotal landmark Phase 3 BOREAS and NOTUS trials, including analyses demonstrating Dupixent reduced exacerbations and improved lung function regardless of whether patients had emphysema. In the pivotal COPD trials, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dupixent-dupilumab-data-presented-ats-130000007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0109394709.USD","LU0289739699.SGD","PT","BK4096","REGN","ATS","LU0114720955.EUR","LU1917777945.USD","LU2362541513.USD","LU2362540622.SGD","LU2468319806.SGD","LU2106854487.HKD","LU2237438978.USD","LU0882574055.USD","LU2089984988.USD","BK4161","LU2362541273.HKD","LU0058720904.USD","LU1974910355.USD","BK4585","LU0053666078.USD","BK4588","LU0889565916.HKD","LU2023250504.SGD","LU0320765992.SGD","LU0823416689.USD","PN","BK4166","BK4139"],"gpt_icon":0},{"id":"2532073898","title":"PureTech Health to Present Promising IPF Trial Results at ATS Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2532073898","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532073898?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:03","pubTimestamp":1746097385,"startTime":"0","endTime":"0","summary":"PureTech Health ( ($GB:PRTC) ) has provided an update. PureTech Health announced that it will present results from its Phase 2b ELEVATE IPF trial o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/puretech-health-to-present-promising-ipf-trial-results-at-ats-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/puretech-health-to-present-promising-ipf-trial-results-at-ats-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATS","BK4161"],"gpt_icon":0},{"id":"2532500381","title":"PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2532500381","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532500381?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"Late-breaking oral presentation to highlight further evidence supporting potential for deupirfenidone to serve as a new standard of care for the treatment of idiopathic pulmonary fibrosis . Regulatory and strategic planning underway to advance deupirfenidone into Phase 3 development. The presentation will highlight data from the recently completed Phase 2b ELEVATE IPF trial of deupirfenidone , which demonstrated unprecedented efficacy outcomes in patients living with idiopathic pulmonary fibrosis , including the potential to stabilize lung function decline at 26 weeks while maintaining safety and tolerability.The Phase 2b ELEVATE IPF trial was a global, randomized, double-blind, active- and placebo-controlled, dose-ranging trial designed to evaluate the efficacy, tolerability, safety, and dosing regimen of deupirfenidone  in patients with IPF compared to pl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/puretech-present-results-phase-2b-110000010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","BK4161","SOC","BK4108","BK4213","BK4139","ATS","AFG","FVC","PRTC","BK4117","LYT"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":122,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-28","symbol":"ATS","fiscalQuarterEnding":"2025/03","expectedEps":0.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1748404800000,"reportTimeType":"post","actualEps":0.28},{"market":"US","date":"2025-02-05","symbol":"ATS","fiscalQuarterEnding":"2024/12","expectedEps":0.23,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1738731600000,"reportTimeType":"pre","actualEps":0.23},{"market":"US","date":"2024-11-06","symbol":"ATS","fiscalQuarterEnding":"2024/09","expectedEps":0.25,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"pre","actualEps":0.18},{"market":"US","date":"2024-08-08","symbol":"ATS","fiscalQuarterEnding":"2024/06","expectedEps":0.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":0.37},{"market":"US","date":"2024-05-16","symbol":"ATS","fiscalQuarterEnding":"2024/03","expectedEps":0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715832000000,"reportTimeType":"pre","actualEps":0.48}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.75,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1745985600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ATS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ATS","date":"2025-07-01","current":-151.173378,"percent":0.002012,"low":-151.382229,"twenty":22.566909,"median":33.413307,"eighty":42.647498,"high":49.784492,"avg":25.119917,"sd":38.589571,"marketCap":3103713303.42},"quantilePoints":[{"date":"2023-06-02","current":46.343344,"twenty":46.194425,"median":46.266425,"eighty":46.306886,"marketCap":4385290976.46},{"date":"2023-06-09","current":46.009827,"twenty":46.17581,"median":46.28258,"eighty":46.915752,"marketCap":4390539453.8},{"date":"2023-06-16","current":45.438012,"twenty":45.320112,"median":46.164952,"eighty":46.476751,"marketCap":4375388926.84},{"date":"2023-06-23","current":48.145057,"twenty":45.487654,"median":46.266425,"eighty":47.860268,"marketCap":4658766213.85},{"date":"2023-06-30","current":46.896248,"twenty":45.651659,"median":46.266425,"eighty":47.485058,"marketCap":4511580364.18},{"date":"2023-07-07","current":46.270844,"twenty":46.009827,"median":46.312962,"eighty":47.5378,"marketCap":4411747145.22},{"date":"2023-07-14","current":48.698172,"twenty":46.043025,"median":46.511353,"eighty":47.780498,"marketCap":4728914205.59},{"date":"2023-07-21","current":48.480908,"twenty":46.105078,"median":46.872979,"eighty":48.286922,"marketCap":4686318579.71},{"date":"2023-07-28","current":45.850462,"twenty":46.043025,"median":46.851428,"eighty":48.286922,"marketCap":4428020690.86},{"date":"2023-08-04","current":44.368411,"twenty":46.009827,"median":46.763285,"eighty":48.152813,"marketCap":4237745227.85},{"date":"2023-08-11","current":42.700705,"twenty":45.438012,"median":46.511353,"eighty":48.145057,"marketCap":4326916372.16},{"date":"2023-08-18","current":40.050115,"twenty":44.926078,"median":46.32649,"eighty":48.075247,"marketCap":4021626143.41},{"date":"2023-08-25","current":41.899702,"twenty":43.443089,"median":46.270844,"eighty":48.061899,"marketCap":4194356348.69},{"date":"2023-08-31","current":43.312379,"twenty":42.678859,"median":46.219245,"eighty":47.836778,"marketCap":4344740041.37},{"date":"2023-09-08","current":43.843953,"twenty":42.897314,"median":46.105078,"eighty":47.634879,"marketCap":4353234860.78},{"date":"2023-09-15","current":43.042951,"twenty":42.657014,"median":45.930144,"eighty":47.433983,"marketCap":4325894000.62},{"date":"2023-09-22","current":41.921548,"twenty":42.559437,"median":45.562117,"eighty":47.311701,"marketCap":4220969734.92},{"date":"2023-09-29","current":42.533222,"twenty":42.508464,"median":45.081733,"eighty":47.274981,"marketCap":4280367687.17},{"date":"2023-10-06","current":40.050115,"twenty":42.428364,"median":44.926078,"eighty":47.160162,"marketCap":3958860964.51},{"date":"2023-10-13","current":39.423877,"twenty":42.00893,"median":44.615828,"eighty":47.035061,"marketCap":3917634187.34},{"date":"2023-10-20","current":36.088795,"twenty":41.126371,"median":44.229891,"eighty":46.935301,"marketCap":3572025991.12},{"date":"2023-10-27","current":34.661554,"twenty":40.778231,"median":44.058847,"eighty":46.909266,"marketCap":3403618402.31},{"date":"2023-11-03","current":33.358105,"twenty":40.050115,"median":43.843953,"eighty":46.860392,"marketCap":3284508208.07},{"date":"2023-11-10","current":31.05346,"twenty":39.978754,"median":43.47968,"eighty":46.850053,"marketCap":3541182846.54},{"date":"2023-11-17","current":33.712074,"twenty":39.645245,"median":43.312379,"eighty":46.711431,"marketCap":3845894896.75},{"date":"2023-11-24","current":33.592349,"twenty":38.190334,"median":43.072078,"eighty":46.623309,"marketCap":3848769791.51},{"date":"2023-12-01","current":33.655362,"twenty":35.166914,"median":42.886392,"eighty":46.541855,"marketCap":3891785593.98},{"date":"2023-12-08","current":33.604952,"twenty":34.322082,"median":42.591477,"eighty":46.44537,"marketCap":3879525100.59},{"date":"2023-12-15","current":35.923838,"twenty":34.218738,"median":42.507736,"eighty":46.366559,"marketCap":4204253502},{"date":"2023-12-22","current":36.07507,"twenty":34.272496,"median":42.474968,"eighty":46.323119,"marketCap":4257700834.69},{"date":"2023-12-29","current":36.289315,"twenty":34.310293,"median":42.423994,"eighty":46.304224,"marketCap":4315633982.44},{"date":"2024-01-05","current":34.650971,"twenty":34.327977,"median":42.161849,"eighty":46.287991,"marketCap":4072504954.25},{"date":"2024-01-12","current":35.442932,"twenty":34.397952,"median":41.910625,"eighty":46.273191,"marketCap":4139113955.77},{"date":"2024-01-19","current":36.274955,"twenty":34.423844,"median":41.655761,"eighty":46.2585,"marketCap":4216951441.35},{"date":"2024-01-26","current":36.917882,"twenty":34.562753,"median":40.778299,"eighty":46.231655,"marketCap":4292072985.19},{"date":"2024-02-02","current":36.987217,"twenty":34.654752,"median":40.235802,"eighty":46.154093,"marketCap":4330447033.68},{"date":"2024-02-09","current":31.2472,"twenty":34.423844,"median":40.050115,"eighty":46.10731,"marketCap":4053209917.9},{"date":"2024-02-16","current":29.911027,"twenty":34.218738,"median":40.010065,"eighty":46.067846,"marketCap":3869003534.07},{"date":"2024-02-23","current":28.569192,"twenty":34.062459,"median":39.908119,"eighty":46.029746,"marketCap":3697982548.6},{"date":"2024-03-01","current":28.954191,"twenty":33.729718,"median":39.700587,"eighty":45.946081,"marketCap":3727658474.68},{"date":"2024-03-08","current":28.897573,"twenty":33.622723,"median":38.630157,"eighty":45.760452,"marketCap":3749905081.21},{"date":"2024-03-15","current":28.33706,"twenty":33.535637,"median":37.535596,"eighty":45.60011,"marketCap":3663186667.6},{"date":"2024-03-22","current":28.378306,"twenty":33.360741,"median":37.125888,"eighty":45.512475,"marketCap":3664397837.7},{"date":"2024-03-28","current":27.463826,"twenty":33.187804,"median":36.956482,"eighty":45.379062,"marketCap":3545999564.77},{"date":"2024-04-05","current":25.261057,"twenty":31.829239,"median":36.880063,"eighty":45.11865,"marketCap":3270651387.12},{"date":"2024-04-12","current":24.173756,"twenty":30.404732,"median":36.432536,"eighty":45.004481,"marketCap":3078077137.88},{"date":"2024-04-19","current":24.609778,"twenty":29.677763,"median":36.289315,"eighty":44.938488,"marketCap":3127556802.58},{"date":"2024-04-26","current":25.396884,"twenty":29.011941,"median":36.169269,"eighty":44.868397,"marketCap":3239367008.29},{"date":"2024-05-03","current":25.125077,"twenty":28.84322,"median":36.062467,"eighty":44.633305,"marketCap":3203669221.23},{"date":"2024-05-10","current":26.025435,"twenty":28.633736,"median":35.997283,"eighty":44.566345,"marketCap":3323128791.91},{"date":"2024-05-17","current":23.786609,"twenty":28.457413,"median":35.841921,"eighty":44.342163,"marketCap":3384597470.53},{"date":"2024-05-24","current":21.936652,"twenty":28.195987,"median":35.701363,"eighty":44.23426,"marketCap":3102092113.2},{"date":"2024-05-31","current":21.435159,"twenty":27.970637,"median":35.598334,"eighty":44.222609,"marketCap":3039383806.02},{"date":"2024-06-07","current":22.690097,"twenty":27.463826,"median":35.382456,"eighty":43.895086,"marketCap":3211638521.11},{"date":"2024-06-14","current":22.285278,"twenty":26.048085,"median":35.173981,"eighty":43.895086,"marketCap":3139567043.35},{"date":"2024-06-21","current":21.323834,"twenty":25.875989,"median":34.8436,"eighty":43.864406,"marketCap":3015344623.92},{"date":"2024-06-28","current":22.482628,"twenty":25.849972,"median":34.751792,"eighty":43.843953,"marketCap":3180274284.27},{"date":"2024-07-05","current":21.972427,"twenty":25.639244,"median":34.657272,"eighty":43.651713,"marketCap":3127376247.29},{"date":"2024-07-12","current":22.998515,"twenty":25.494281,"median":34.422199,"eighty":43.533747,"marketCap":3270585876.4},{"date":"2024-07-15","current":22.953023,"twenty":25.430859,"median":34.413972,"eighty":43.516271,"marketCap":3254489261.98},{"date":"2024-08-02","current":20.309458,"twenty":25.403679,"median":34.373922,"eighty":43.501635,"marketCap":2841766295.19},{"date":"2024-08-09","current":20.723514,"twenty":25.129607,"median":34.224644,"eighty":43.440249,"marketCap":2735666122.5},{"date":"2024-08-16","current":19.860035,"twenty":24.796645,"median":34.162619,"eighty":43.405587,"marketCap":2630022203.9},{"date":"2024-08-23","current":19.838448,"twenty":24.268888,"median":33.920018,"eighty":43.283252,"marketCap":2645505418.49},{"date":"2024-08-30","current":19.471469,"twenty":23.8321,"median":33.734128,"eighty":43.147809,"marketCap":2621186477.04},{"date":"2024-09-06","current":18.602592,"twenty":23.494241,"median":33.671115,"eighty":43.072078,"marketCap":2495925620.93},{"date":"2024-09-13","current":19.185441,"twenty":22.907687,"median":33.604952,"eighty":43.042951,"marketCap":2560815499.76},{"date":"2024-09-20","current":20.831449,"twenty":22.803751,"median":33.570295,"eighty":43.028387,"marketCap":2786196948.41},{"date":"2024-09-27","current":21.948725,"twenty":22.594145,"median":33.45372,"eighty":42.744396,"marketCap":2956487278.6},{"date":"2024-10-04","current":21.646505,"twenty":22.472834,"median":33.3614,"eighty":42.700705,"marketCap":2900362552.24},{"date":"2024-10-11","current":21.560157,"twenty":22.285278,"median":33.233174,"eighty":42.591477,"marketCap":2843647655.11},{"date":"2024-10-18","current":22.617927,"twenty":22.261739,"median":32.698187,"eighty":42.533222,"marketCap":2977792893.11},{"date":"2024-10-25","current":22.645897,"twenty":22.285278,"median":31.73976,"eighty":42.511377,"marketCap":2967565955.08},{"date":"2024-10-31","current":23.088453,"twenty":22.329808,"median":31.05346,"eighty":42.505551,"marketCap":3006452868.32},{"date":"2024-11-08","current":30.478219,"twenty":22.389519,"median":30.568298,"eighty":42.486619,"marketCap":2853731574.85},{"date":"2024-11-15","current":30.530988,"twenty":22.401664,"median":30.478219,"eighty":42.476424,"marketCap":2830133907.78},{"date":"2024-11-22","current":30.757144,"twenty":22.402758,"median":30.568681,"eighty":42.451666,"marketCap":2862659955.58},{"date":"2024-11-29","current":33.961013,"twenty":22.434826,"median":30.673837,"eighty":42.419625,"marketCap":3148783777.17},{"date":"2024-12-06","current":34.669633,"twenty":22.46611,"median":30.907914,"eighty":42.257969,"marketCap":3210086264.85},{"date":"2024-12-13","current":33.207161,"twenty":22.47871,"median":31.108842,"eighty":42.148741,"marketCap":3040755582.89},{"date":"2024-12-20","current":31.48838,"twenty":22.488641,"median":31.48838,"eighty":42.00893,"marketCap":2849502272.41},{"date":"2024-12-27","current":33.734858,"twenty":22.494713,"median":31.970845,"eighty":41.91281,"marketCap":3041459063.87},{"date":"2025-01-03","current":33.410701,"twenty":22.507997,"median":32.326091,"eighty":41.867662,"marketCap":3006099952.21},{"date":"2025-01-10","current":30.583758,"twenty":22.548751,"median":32.187154,"eighty":41.739502,"marketCap":2758779888.76},{"date":"2025-01-17","current":28.714206,"twenty":22.594145,"median":31.76484,"eighty":41.57202,"marketCap":2591110278.91},{"date":"2025-01-24","current":30.922991,"twenty":22.613171,"median":31.446918,"eighty":40.977822,"marketCap":2794075415.08},{"date":"2025-01-31","current":29.754521,"twenty":22.627085,"median":31.164224,"eighty":40.788494,"marketCap":2682414705.78},{"date":"2025-02-07","current":44.52783,"twenty":22.642592,"median":31.108842,"eighty":40.977822,"marketCap":2778433490.84},{"date":"2025-02-14","current":46.096561,"twenty":22.681257,"median":31.405456,"eighty":41.965239,"marketCap":2894690862.79},{"date":"2025-02-21","current":45.29574,"twenty":22.741461,"median":31.73976,"eighty":42.419625,"marketCap":2847627453.27},{"date":"2025-02-28","current":46.79865,"twenty":22.792532,"median":32.079,"eighty":42.507008,"marketCap":2895255396.7},{"date":"2025-03-07","current":41.862084,"twenty":22.806185,"median":32.332694,"eighty":42.635168,"marketCap":2622361985.36},{"date":"2025-03-14","current":41.423278,"twenty":22.822194,"median":32.713389,"eighty":42.635168,"marketCap":2565848922.04},{"date":"2025-03-21","current":43.880591,"twenty":22.853037,"median":32.981006,"eighty":43.034213,"marketCap":2732813300.12},{"date":"2025-03-28","current":42.224099,"twenty":22.88278,"median":33.123373,"eighty":43.054602,"marketCap":2633489494.72},{"date":"2025-04-04","current":39.042756,"twenty":22.901877,"median":33.222238,"eighty":43.034213,"marketCap":2482102274.67},{"date":"2025-04-11","current":36.168577,"twenty":22.907687,"median":33.258379,"eighty":42.953904,"marketCap":2303349084},{"date":"2025-04-17","current":36.662234,"twenty":22.91307,"median":33.3614,"eighty":42.840307,"marketCap":2360722684.91},{"date":"2025-04-25","current":38.011562,"twenty":22.933896,"median":33.415912,"eighty":42.72692,"marketCap":2443342344.25},{"date":"2025-05-02","current":38.318726,"twenty":22.957542,"median":33.501164,"eighty":42.694361,"marketCap":2471450690},{"date":"2025-05-09","current":38.494248,"twenty":22.972956,"median":33.554541,"eighty":42.647498,"marketCap":2471983722.75},{"date":"2025-05-16","current":42.432532,"twenty":22.990951,"median":33.59865,"eighty":42.694361,"marketCap":2705638771.71},{"date":"2025-05-23","current":39.240219,"twenty":23.03449,"median":33.649379,"eighty":42.706785,"marketCap":2525720011.68},{"date":"2025-05-30","current":-145.081888,"twenty":22.98843,"median":33.649379,"eighty":42.736874,"marketCap":2948051518.8},{"date":"2025-06-06","current":-141.392185,"twenty":22.910379,"median":33.59865,"eighty":42.706785,"marketCap":2905577142.42},{"date":"2025-06-13","current":-147.065973,"twenty":22.838868,"median":33.554541,"eighty":42.705569,"marketCap":3029340885.66},{"date":"2025-06-20","current":-147.588101,"twenty":22.775703,"median":33.508702,"eighty":42.700705,"marketCap":3013637808.62},{"date":"2025-06-27","current":-151.382229,"twenty":22.617927,"median":33.434816,"eighty":42.684845,"marketCap":3112877198.05},{"date":"2025-07-01","current":-151.173378,"twenty":22.566909,"median":33.413307,"eighty":42.647498,"marketCap":3103713303.42}],"updateTime":1751453435985}}}